Clinical trials: Liver Steatoses
Psoriasis, Fatty Liver
Lifestyle Modification in Psoriatic Patients With Fatty Liver
Several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease (NAFLD) in those with psoriasis, which may reflect the increased occurrence of metabolic syndrome in this patient population.
- Trial name
- NCT05125757
- Testing
- lifestyle modification, usual lifestyle
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
NAFLD
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.
- Trial name
- NCT03261739
- Testing
- RYI-018
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 84 people
- Sponsor
- Bird Rock Bio, Inc.
Liver Steatoses
Observational and Prospective Study of Hepatic Steatosis and Related Risk Factors Using Ultrasound and Artificial Intelligence
Fatty liver is the most frequent chronic liver disease worldwide and ultrasonography is widely employed for diagnosis. The accuracy of this technique, however, is strongly operator-dependent.
- Trial name
- ST-AI (NCT06103175)
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Bari
Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver biochemistry tests in the world. The prevalence rate of NAFLD has been reported to be 30-40% in men and 15-20% in women, up to 70% of people with…
- Trial name
- NCT04059029
- Testing
- Bariatric surgery
- Volunteers
- 200 people
- Sponsor
- Taipei Medical University Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)
This study will assess the inter-center reproducibility and accuracy of hepatic fat fraction measurements using up to two MRI-based methods.
- Trial name
- NCT01110577
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Liver Cancer, Liver Metastases
Impact of Minimally Invasive and Open Liver Surgery in Different BMI-classes
Despite the worldwide increase of both obesity and use of minimally invasive liver surgery(MILS), evidence regarding the safety and eventual benefits of MILS in obese patients is scarce.
- Conditions
- Liver Cancer, Liver Metastases, Obesity
- Trial name
- MILSOBES (NCT05475054)
- Testing
- Minimally invasive liver resection
- Where
- Italy
- Volunteers
- 9,963 people
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
NAFLD, Obesity
Vigabatrin and Insulin Sensitivity
Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity and is associated with an increased risk of developing type 2 diabetes.
- Trial name
- NCT04321395
- Testing
- Vigabatrin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Non-alcoholic Steatohepatitis
Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH
There is a clear unmet clinical need for effective lifestyle intervention in patients with nonalcoholic steatohepatitis (NASH). Patients have self-identified multiple barriers to effective lifestyle intervention can be removed…
- Trial name
- NCT04872777
- Testing
- Noom Healthy Weight
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Milton S. Hershey Medical Center
Non-Alcoholic Fatty Liver Disease
Micro RNA Levels in NAFLD
Epidemiological study of NAFLD, NASH patients. Descriptions of altered miRNA profiles in NAFLD patients especially with fibrosis.
- Trial name
- NCT04574557
- Testing
- micro RNA
- Volunteers
- 80 people
- Sponsor
- Assiut University
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide and is a major cause of cirrhosis and liver cancer in Western countries.
- Trial name
- NCT04241575
- Testing
- Simple fibrosis scores and electronic reminder messages
- Where
- Hong Kong
- Volunteers
- 1,061 people
- Sponsor
- Chinese University of Hong Kong
Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Antidiabetic Effects on Intrahepatic Fat
This was a 24-week single-center, open-label, parallel controlled group comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease.
- Trial name
- NCT03068065
- Testing
- Liraglutide, Metformin, Gliclazide
- Where
- China
- Volunteers
- 87 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatitis C, Hepatitis B
Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis.
- Conditions
- Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- ELF (NCT02044523)
- Testing
- Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus
Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.
Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement…
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus, Hypertension, Hyperlipidaemia
- Trial name
- NCT07025980
- Testing
- The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS
- Where
- Croatia
- Volunteers
- 114 people
- Sponsor
- Eva Cubric
Non-alcoholic Fatty Liver Disease
A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to investigate whether a new medicine, called mitoquinone, will reduce raised liver enzymes due to NAFLD and to see if it is safe.
- Trial name
- MARVEL (NCT01167088)
- Testing
- Mitoquinone mesylate
- Where
- United Kingdom
- Volunteers
- 110 people
- Sponsor
- Antipodean Pharmaceuticals, Inc.
NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, Metabolic Syndrome
- Trial name
- PROMETEO (NCT04371042)
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Time Restricted Feeding, Exercise
Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity
In Spain, overweight and obesity prevalence is reaching 70% in men and 50% in women. Excess of triglycerides are usually stored in the subcutaneous adipose tissue (SAT), until a point where SAT is unable to expand further.
- Conditions
- Time Restricted Feeding, Exercise, Hepatic Steatosis, Cardiometabolic Syndrome
- Trial name
- TEMPUS (NCT05897073)
- Testing
- Time-restricted eating intervention, Exercise intervention, Time-restricted eating plus exercise intervention
- Where
- 2 sites in Spain
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
Binge Drinking, Liver Injury
Metabolic Changes in Healthy Subjects with Acute Binge Drink
The goal of this double-blinded, randomized trial is to investigate the effects of acute binge drinking on liver function, liver fat content, and lipid metabolism in healthy young subjects.
- Conditions
- Binge Drinking, Liver Injury, Hepatic Steatosis
- Trial name
- MeABD (NCT06298318)
- Testing
- Vodka, water
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Zhejiang Chinese Medical University
NASH - Nonalcoholic Steatohepatitis, NAFLD
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
A multi-centre randomised controlled trial to determine the implementation and health care cost of LiverMultiScan vs. routine methodical assessment (standard care) of Non-alcoholic fatty liver disease (NAFLD) across several…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, Metabolic Syndrome
- Trial name
- RADIcAL1 (NCT03289897)
- Testing
- LiverMultiScan
- Where
- 11 sites in Germany, Netherlands and 2 more
- Volunteers
- 801 people
- Sponsor
- Perspectum
Heterozygous Familial Hypercholesterolemia
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
- Trial name
- STEATO-FH (NCT06634160)
- Testing
- Fibroscan, Sample collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital